Skip to content Skip to footer

Convergence of Western Science and Traditional Chinese Medicine — Botanical Cancer Drug Platform

THE CHALLENGE —Unmet Medical Need for Holistic Cancer Treatment Cancer is a heterogeneous disease. Heterogeneity in cancer is not limited to differences between different patients, but also occurs within a single patient. This intrapatient or intratumoral heterogeneity can present great challenges for cancer treatment. This…

Read More

Asian Fund for Cancer Research Announces Inaugural 2020 BRACE Award Venture Competition Winner 

FOR IMMEDIATE RELEASE: 7 April 2021 CONTACTS: Asian Fund for Cancer Research Bradley Gillenwater, Senior Director for Corporate Engagement E-mail: bgillenwater@afcr.org Hugill & Ip Solicitors Marco Raccuia, Head of Finance & Operations E-mail: marco.raccuia@hugillandip.com Asian Fund for Cancer Research Announces Inaugural BRACE Award Venture Competition Winner  Gastrointestinal Cancer Drug Developer Arbele Receives…

Read More

High Impact Collaboration — Developing Next-Generation Inhibitors to a Key Cancer Pathway

THE CHALLENGE —Tackling the Pre-Clinical Experiments to Overcome Drug Resistance Many patients with melanoma, papillary thyroid tumors, serous ovarian tumors, and colorectal tumors, for example, have DNA mutations that hyperactivate the major cell growth and survival pathway Ras/Raf/MEK/ERK, causing abnormal growth and cancer. Unfortunately, patients…

Read More